{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li Y"],"funding":["Shanghai Clinical Medical Research Center Project","Shanghai Agriculture Applied Technology Development Program Project","NSFC","Shanghai Municipal Education Commission Project","National Natural Science Foundation of China","Ministry of Science and Technology of China Project","Shanghai Municipal Health Commission Project","Shanghai Municipal Science and Technology Project","National Innovation Special Zone Project","Shanghai Jiao Tong University Projects"],"pagination":["e629"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8574956"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(11)"],"pubmed_abstract":["Tacrolimus (FK506) and rapamycin (RAPA) are widely used to maintain long-term immunosuppression after organ transplantation. However, the impact of accumulative drug administration on the recipients' immune systems remains unclear. We investigated the impact of 3-year FK506 or RAPA treatment after renal transplantation on the human immune systems. A discovery cohort of 30 patients was first recruited, and we discovered two distinctive T lineage suppressive regulatory patterns induced by chronic treatment of FK506 and RAPA. The increased percentage of senescent CD8<sup>+</sup> CD57<sup>+</sup> T lineages and less responsive T cell receptor (TCR) pathway in the FK506 group indicate better graft acceptance. Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were bot"],"journal":["Clinical and translational medicine"],"pubmed_title":["Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry."],"pmcid":["PMC8574956"],"funding_grant_id":["18430760500","81902587","2020 SJTU-HUJI","2017ZX10203205-006-002","G20180101","19X190020154","ZH2018QNA49","ZH2018QNA54","SD0820016","19MC1910800","ZXWF082101","YG2016MS60","Agri-X20200101","SL2020MS026","YG2016QN24","017SHZDZX01","22077079","2019CXJQ03","ZH2018ZDA01","81871448"],"pubmed_authors":["Li Y","Ding X","Zhang T","Wang B","Hong Y","Zhou P","Jiang H","An H","Shen C"],"additional_accession":[]},"is_claimable":false,"name":"Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry.","description":"Tacrolimus (FK506) and rapamycin (RAPA) are widely used to maintain long-term immunosuppression after organ transplantation. However, the impact of accumulative drug administration on the recipients' immune systems remains unclear. We investigated the impact of 3-year FK506 or RAPA treatment after renal transplantation on the human immune systems. A discovery cohort of 30 patients was first recruited, and we discovered two distinctive T lineage suppressive regulatory patterns induced by chronic treatment of FK506 and RAPA. The increased percentage of senescent CD8<sup>+</sup> CD57<sup>+</sup> T lineages and less responsive T cell receptor (TCR) pathway in the FK506 group indicate better graft acceptance. Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were bot","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-08T20:31:21.326Z","creation":"2022-02-11T13:28:48.861Z"},"accession":"S-EPMC8574956","cross_references":{"pubmed":["34841735"],"doi":["10.1002/ctm2.629"]}}